Age-less Explained: Did America Just Legalize Peptides?

Everyone’s asking whether peptides are now legal in America. In this episode of The Science of Age-less Living, Dr Ethan Hausman-Marquis cuts through the headlines. He explains how US pharmacy compounding works and why the FDA moved peptides like BPC-157 and TB-500 out of its “significant safety concerns” category in April 2026. He also covers what really happened in July, when an FDA advisory committee voted to recommend six peptides for compounding, even though the agency’s own scientists had recommended against all of them.

He then unpacks the October 2026 HHS policy that lets licensed US pharmacies compound six peptides, BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, without enforcement action, and the strict conditions attached. Products need a prescription, and the peptide has to come from a registered manufacturer. Each product can contain only one peptide, and side effects have to be reported. The policy is temporary, can be withdrawn, and doesn’t approve anything. Meanwhile, the FDA is cracking down hard on online “research use only” sellers.

Finally, the episode looks at what all this means outside the US. American policy doesn’t change the law in the UK, Australia or Europe, and Australia has gone in almost the opposite direction. Dr Hausman-Marquis explains why “FDA cleared” marketing is a red flag, and what the US rules quietly admit about the quality of research-chemical vials. He ends with the point that matters most: a policy change doesn’t create evidence. The next FDA committee meeting, due by February 2027, will look at five more peptides, including GHK-Cu and melanotan II.